我国药品专利侵权案件实证分析  

Empirical analysis of drug patent infringement cases in China

作　　者：李奕瑾 曹丽荣 LI Yi-jin;CAO Li-rong(Shanghai International Intellectual Property Institute,Tongji University,Shanghai 200092,China)

机构地区：[1]同济大学上海国际知识产权学院,上海200092

出　　处：《中国新药杂志》2023年第3期224-230,共7页Chinese Journal of New Drugs

基　　金：2022年国家社会科学基金年度一般项目(22BFX192)。

摘　　要：本文梳理分析了自1995年—2020年10月我国国内的药品专利侵权案件,分别从案件受理年份、诉讼主体、涉案药品类别、案件审理级别、案件结论等维度进行实证分析。由上述统计分析可知,我国化学药的专利侵权案件数量最多,占比53.3%,其次为中药专利侵权案件,数量占比30.7%,生物药专利侵权诉讼案件占比16%。在我国国内药品专利中,药品的“基础专利”多掌握在国外原研制药企业手中,原研制药企业通过围绕“基础专利”进行专利布局,积极利用专利诉讼策略。本文结合实证研究,探讨了我国制药企业专利工作具体策略。This paper combs and analyzes the drug patent infringement cases in China from 1995 to October 2020. The empirical analysis was carried out from the dimensions of the year of case acceptance, the subject of litigation, the type of drug involved, the level of adjudication and the case conclusion. According to the above statistical analysis, the number of patent infringement cases of chemical drugs in China is the largest, accounting for 53.3%, followed by that of traditional Chinese drugs and biological drugs in China, accounting for 30.7% and 16%, respectively. In drug patents in China, the “basic patents” of drugs are mostly held by foreign companies that own the original patented drugs. They build patent portfolio around the “basic patents” and actively use patent litigation strategy. Combined with empirical research, this paper discusses the specific strategies of patent work of pharmaceutical companies in China.

关 键 词：药品专利 统计分析 专利侵权 专利策略 

分 类 号：R95[医药卫生—药学]